Recurrent pregnancy loss affects an estimated one in a hundred couples trying to build a family, yet in a striking proportion of cases no cause is ever identified, leaving patients and clinicians alike without answers. A new study from researchers at the Institute of Medical Sciences, Banaras Hindu University in Varanasi, India, published in the journal Biochemical Genetics, offers a detailed picture of the genetic abnormalities lurking in lost pregnancies and points to a two-tier testing strategy that could substantially improve diagnostic yield. Combining rapid aneuploidy screening with high-resolution chromosomal microarray analysis and a layer of computational biology, the team has mapped not only which chromosomes go wrong in recurrent miscarriage but also which biological pathways those errors may disrupt.

The research team, led by Shivani Mishra and corresponding author Royana Singh, recruited 125 fetal specimens from pregnancies that ended in loss, ultimately analyzing 118 samples after applying predefined exclusion criteria designed to guard against contamination and degraded tissue. The specimens, which included products of conception and fetal tissues such as skin, muscle, and cartilage obtained during autopsy, underwent DNA extraction and quantitative fluorescent PCR, a technique that amplifies short tandem repeat markers scattered across chromosomes 13, 18, 21, X, and Y. By measuring the relative quantity of fluorescent signals at these markers, QF-PCR can detect the most common whole-chromosome imbalances, the trisomies and monosomies that account for the majority of chromosomally abnormal miscarriages, often within a day or two of sample receipt.

The results were sobering but clinically rich. Of the 118 samples analyzed, QF-PCR identified aneuploidy in 36 cases, a detection rate of 30.5 percent. Twenty of these were monosomies, in which an entire chromosome is missing from the fetal genome, and sixteen were trisomies, in which an extra copy is present. The remaining 82 samples appeared normal by this rapid screen. That nearly one in three lost pregnancies carried a whole-chromosome imbalance confirms the central role of aneuploidy in early pregnancy failure, and it also carries a practical message for genetic counseling: when an aneuploidy is identified as the cause of a loss, the recurrence risk for future pregnancies is generally low, information that can meaningfully reduce anxiety for couples facing the aftermath of repeated loss.

Beyond the raw detection numbers, the study teased out clinical associations that matter for patient management. Maternal age showed a statistically significant relationship with the presence of chromosomal abnormalities, echoing decades of reproductive biology linking the aging oocyte to meiotic segregation errors. More intriguing was the finding of a weak but statistically significant negative correlation between gestational age and aneuploidy risk, with a correlation coefficient of −0.238 and a p-value of 0.008855. In other words, the earlier the loss, the more likely it was to be chromosomally abnormal, a pattern consistent with the idea that grossly imbalanced embryos tend to fail early in development, while losses later in gestation are more often driven by other mechanisms, including immunological, endocrine, thrombotic, and anatomical factors.

But QF-PCR has a well-known blind spot. It interrogates a limited set of chromosomes and cannot see submicroscopic copy number variations, the deletions and duplications of genomic segments too small to alter chromosome number but large enough to remove or duplicate genes. To peer beneath that resolution floor, the team selected a subset of 30 samples, stratified by their QF-PCR outcomes, and subjected them to array comparative genomic hybridization. In aCGH, differentially labeled fetal and reference DNA are co-hybridized to a microarray carrying hundreds of thousands of immobilized genomic probes, and the fluorescence ratio at each probe reveals whether the corresponding region is deleted or duplicated in the fetal genome. This technique can detect imbalances ranging from roughly 100 kilobases upward, an order of magnitude finer than conventional karyotyping.

The aCGH analysis proved its worth. Within the 30-sample cohort, the researchers identified clinically relevant copy number variations spanning the spectrum of pathogenicity, including pathogenic and likely pathogenic variants as well as variants of uncertain significance, the latter category reflecting regions whose dosage sensitivity has not yet been firmly established. Each variant was interpreted according to the joint guidelines of the American College of Medical Genetics and the Clinical Genome Resource, the standard framework that weighs factors such as gene content, inheritance pattern, and overlap with established disease loci before assigning a clinical classification.

Among the genes caught in deleted or duplicated segments were several with compelling biological narratives. CFHR3, a member of the complement factor H-related gene family, participates in the regulation of the complement cascade, the arm of innate immunity whose dysregulation has been implicated in inflammatory damage at the maternal-fetal interface. TNFRSF4 encodes a tumor necrosis factor receptor superfamily member with roles in immune cell signaling and tolerance. UGT2B17 belongs to the uridine diphosphate glucuronosyltransferase family, a set of metabolic detoxification enzymes whose variation has previously been linked to recurrent miscarriage, possibly through altered clearance of environmental and endogenous compounds. CD24 and MSR1 are involved in immune signaling and macrophage scavenger function, respectively, while the pregnancy-specific glycoprotein gene family, or PSG genes, is expressed almost exclusively in the placenta and is thought to modulate maternal immune tolerance of the fetus.

To move from gene lists to mechanism, the authors turned the implicated genes loose on a battery of bioinformatics tools. Using FunRich and WebGestalt for functional annotation, KEGG for pathway enrichment, and STRING for protein-protein interaction network construction, the team asked what biological themes united the disrupted loci. The answer converged on a coherent set of processes: immune-inflammatory signaling, endocrine regulation, lipid metabolism, extracellular matrix remodeling, and placental development. The involvement of TNF receptor signaling, MAPK cascades, and interleukin-1-related pathways emerged from the network analyses, weaving the copy number variations into the same immunological tapestry that independent studies have implicated in unexplained recurrent loss, including work on maternal B cell signaling and natural killer cell-mediated immunopathology.

The authors are careful, appropriately so, to frame the pathway findings as exploratory. The cohort of 30 microarray samples is modest, and several of the variants of uncertain significance may prove benign as genomic databases mature. The statistical associations between individual CNVs and miscarriage phenotypes will require validation in larger, well-powered cohorts with matched controls before they can inform clinical decision-making. Still, the architectural message of the study is clear: sequential testing with QF-PCR followed by aCGH captures abnormalities that neither method detects alone, and it does so at a fraction of the cost and turnaround time of broader approaches such as whole-genome sequencing.

That message lands at a moment of ferment in reproductive genetics. European Society of Human Reproduction and Embryology guidelines define recurrent pregnancy loss as two or more consecutive losses, and professional societies have been wrestling with the optimal diagnostic workup of lost pregnancy tissue for years. Previous studies comparing karyotyping with molecular methods have shown that conventional cytogenetics suffers from culture failure and maternal cell contamination, problems that DNA-based methods largely sidestep. The Banaras Hindu University team’s approach, anchored in a real clinical diagnostic laboratory serving a population with limited access to advanced genomic testing, demonstrates that a tiered molecular protocol is feasible and productive outside of well-funded Western centers.

For couples enduring the grief of repeated loss, the study’s findings translate into a concrete recommendation worth discussing with a genetic counselor: comprehensive cytogenetic analysis of lost pregnancy tissue is not merely an academic exercise. Identifying an aneuploidy or a pathogenic copy number variant can close the diagnostic loop, refine recurrence risk estimates, and in some cases guide the management of subsequent pregnancies, including targeted prenatal or preimplantation genetic testing. Conversely, a normal molecular karyotype redirects the clinical search toward the non-genetic contributors, from antiphospholipid syndrome to uterine anomalies.

The work also adds to a growing map of the genomic landscape of pregnancy failure, in which the PSG gene cluster on chromosome 19, the complement factor H-related locus, and immune receptor genes recur across independent cohorts. As genome-wide datasets accumulate and functional studies test the dosage sensitivity of these loci, variants of uncertain significance will gradually be reclassified, and the exploratory pathway signals reported here may harden into causal mechanisms. Until then, the study stands as both a practical diagnostic template and a hypothesis-generating catalog of the fragile genetic architecture underlying one of medicine’s most quietly devastating problems.

Il tumore al colon-retto è diventato la principale causa di morte per neoplasia tra le persone sotto i 50 anni. Oggi un caso su cinque colpisce persone con meno di 54 anni, mentre trent'anni fa la proporzione era di uno su dieci. Per evitare che i primi sintomi vengano erroneamente attribuiti a disturbi comuni come stitichezza o emorroidi, l'American College of Surgeons (ACS), guidato in questa iniziativa da esperti come Marylise Boutros, Paula Denoya e James T. McCormick, ha introdotto una checklist informativa per orientare le visite mediche. Tra i campanelli d'allarme più significativi figura il sanguinamento rettale ricorrente, che nei giovani adulti aumenta di 8,5 volte la probabilità di diagnosi tumorale. Altri segnali da non sottovalutare includono alterazioni persistenti dell'alvo (stipsi, diarrea, feci sottili), senso di svuotamento incompleto, muco, perdita di peso ingiustificata e affaticamento continuo. Sebbene gli screening di routine siano raccomandati dai 45 anni per i soggetti a rischio medio, la presenza di familiarità o patologie come morbo di Crohn e colite ulcerosa richiede esami precoci, individuando tramite colonscopia la presenza di polipi prima che evolvano.

A groundbreaking study from Mass General Brigham Neuroscience Institute has uncovered crucial genetic underpinnings of congenital cerebral ventriculomegaly (CCV), a disorder characterized by the abnormal swelling of fluid-filled brain ventricles in fetuses. Frequently observed alongside autism spectrum disorder and other neurodevelopmental conditions, CCV has long been a clinical challenge due to its complex origins and unpredictable outcomes.

By analyzing genetic data from approximately 2,700 children diagnosed with CCV and their parents, researchers identified rare, deleterious mutations affecting genes integral to early brain development. These genes regulate the growth and organization of neural cells critical to forming the cerebral cortex—the brain’s center for cognition, memory, and language. Notably, mouse models in which these genes were silenced exhibited enlarged ventricles, linking genetic abnormalities directly to functional and structural brain defects.

This pioneering work shifts the medical understanding of CCV from purely a cerebrospinal fluid circulation disorder to one deeply rooted in developmental brain pathology. It suggests that the ventricular system’s dysfunction reflects a broader impairment in neural circuit formation and brain architecture, potentially explaining why many infants with CCV experience developmental delays and an increased risk of autism.

The implications of these findings are profound. Prenatal neuroimaging combined with targeted genetic screening could enable earlier diagnosis of at-risk fetuses, opening the door to timely interventions before the onset of symptoms. Current neurosurgical treatments, while often lifesaving, do not consistently improve neurological outcomes and expose patients to risks such as infections and lifelong shunt dependency.

Kristopher T. Kahle, MD, PhD, Chief of Pediatric Neurosurgery at Mass General Brigham and senior author of the study, emphasizes the potential of genomic testing to revolutionize patient care. He anticipates that genetic profiling could refine clinical decisions, distinguishing patients who would benefit from surgery from those better served by alternative therapies.

The study’s integration of human genetic analysis with animal modeling represents a paradigm shift, enhancing our grasp of how genetic mutations disrupt cerebrospinal fluid dynamics and cerebral cortex development simultaneously. This dual perspective is poised to stimulate further research aimed at therapeutic innovations targeting the molecular roots of CCV.

Ultimately, this research underscores a critical nexus between developmental neurogenetics and pediatric neurosurgery, offering hope for improved diagnostic precision and personalized treatment strategies. With continued advancements, clinicians may one day prevent or mitigate the neurodevelopmental disabilities often associated with ventriculomegaly, improving quality of life for countless affected children.

Subject of Research: Human tissue samples
Article Title: Developmental genetic determinants of the human cerebrospinal fluid-ventricular system
News Publication Date: —
Web References: https://doi.org/10.1126/scitranslmed.aec4386
References: Allington G et al. Science Translational Medicine. DOI: 10.1126/scitranslmed.aec4386
Keywords: Hydrocephalus, Congenital cerebral ventriculomegaly, Neurodevelopmental disorders, Autism spectrum disorder, Pediatric neurosurgery, Genomic testing

Chromosome instability and aneuploidy have long posed a conundrum in cancer biology, profoundly shaping tumor genomes yet remaining challenging to decode functionally. In a groundbreaking study published in Nature, Al-Zahrani et al. unveil a novel approach, CRISPR-KOALA, that systematically links large-scale chromosomal alterations to specific cancer-driving genes in basal-like breast cancer (BLBC).

BLBC, a highly aggressive subtype characterized by extensive copy-number alterations (CNAs), often harbors arm-level chromosomal imbalances whose contribution to tumorigenesis remains elusive. The researchers developed CRISPR-KOALA to conduct high-throughput bidirectional genetic screens directly in immunocompetent mouse models, overcoming previous barriers related to the complexity and scale of genes affected by aneuploidy.

By focusing on the ten most frequent human chromosome-arm alterations seen in BLBC, the team screened over 3,700 mouse orthologues of genes located on these arms. The screen identified 90 putative cancer driver genes—a majority of which had not been previously linked to cancer—revealing a diverse functional landscape shaping tumor biology. Among the implicated pathways were key signaling networks such as MAPK, HIPPO, and WNT, highlighting the heterogeneity intrinsic to BLBC progression.

Strikingly, manipulating these driver genes in Trp53-mutant mouse models was sufficient to bypass the need for whole-arm CNAs, suggesting that tumors exploit specific genes within broad chromosomal alterations to fuel oncogenesis. This finding challenges the traditional view that arm-level aneuploidies function merely as genomic chaos, instead presenting them as evolutionary selections for particular drivers.

One gene, PLGRKT, localized on chromosome 9p, emerged as a potent oncogene. The team showed that PLGRKT promotes tumor growth by enhancing mitochondrial robustness and boosting reactive oxygen species detoxification. This mechanistic insight connects chromosomal instability not only to genetic selection but also to metabolic adaptations that support cancer cell survival under stress.

Overall, this study delivers a transformative platform and a compendium of cancer drivers that illuminate how aneuploidy sculpts tumor heterogeneity. By delineating driver genes nested within widespread CNAs, it provides an invaluable resource for targeting breast cancer’s genetic complexity with greater precision.

The implications extend beyond breast cancer, offering a blueprint for dissecting arm-level aneuploidy in diverse malignancies. As cancer therapies increasingly focus on genetic vulnerabilities, CRISPR-KOALA represents a leap toward untangling the intricate link between chromosome-level alterations and oncogenic processes.

This work underscores the power of integrating genomic data with functional genetics in vivo, setting the stage for novel drug targets and therapeutic strategies aimed at the underexplored realm of aneuploidy-driven tumorigenesis.

---

Subject of Research: Chromosome instability and cancer driver genes in basal-like breast cancer

Article Title: Aneuploidy selects for the acquisition of driver genes in breast cancer

Article References:
Al-Zahrani, K.N., Langille, E.R., Nurtanto, J. et al. Aneuploidy selects for the acquisition of driver genes in breast cancer. Nature (2026). https://doi.org/10.1038/s41586-026-10752-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41586-026-10752-9

A new soft ultrasound patch is designed to provide long-term, hands-free monitoring of fetal health in real time. Engineers at the University of California, San Diego, have developed a soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time while maintaining reliable performance even as the fetus and umbilical cord [...]